Economic Goals - The GDP growth target for 2026 is set at 4.5%-5%, a decrease from the 5% target in 2025[3] - The weighted average GDP growth target for local governments in 2026 is approximately 5.10%, down from 5.37% in 2025[3] - The urban surveyed unemployment rate target for 2026 is around 5.5%[3] Fiscal Policy - The fiscal deficit rate for 2026 is planned at around 4%, consistent with 2025, amounting to approximately 5.89 trillion yuan, an increase of 230 billion yuan from 2025[3] - General public budget expenditure is expected to reach 30 trillion yuan for the first time, an increase of about 1.27 trillion yuan from the previous year[3] Monetary Policy - The monetary policy remains "moderately loose," with expectations for potential interest rate cuts in the second half of 2026, estimated at 25 basis points for reserve requirement ratio and 10 basis points for interest rates[5] - The issuance of new policy financial instruments is set at 800 billion yuan to stimulate investment[5] Consumption and Investment - A special fund of 1 trillion yuan will be established to promote domestic demand, alongside 2.5 trillion yuan in special bonds for consumer goods replacement[6] - Central budget investment for 2026 is planned at 755 billion yuan, an increase of 20 billion yuan from 2025[6] Green Energy and Innovation - The report emphasizes the development of future industries such as future energy and brain-computer interfaces, with hydrogen production capacity expected to exceed 5 million tons per year by the end of 2024[7] - A national low-carbon transition fund will be established to support green transformation efforts[9]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [5] Core Insights - The 2026 Government Work Report emphasizes the development of emerging industries such as biopharmaceuticals and brain-computer interfaces, alongside initiatives to enhance healthcare services and insurance systems [1][2] - The introduction of a commercial health insurance innovation drug catalog is expected to improve the commercialization environment for innovative drugs, marking a shift towards a multi-payment structure in healthcare [2] - The report highlights the potential for AI in healthcare and the significance of brain-computer interfaces as future industries, indicating a focus on ethical, regulatory, and commercialization pathways [3] Summary by Sections Government Initiatives - The report outlines government plans to implement a strong healthcare foundation, enhance pediatric and mental health services, and improve disease prevention measures, including a budget allocation of 200 billion yuan for medical equipment upgrades [1][3] Commercial Health Insurance - The establishment of a dedicated commercial health insurance drug catalog is anticipated to alleviate the reliance on national basic medical insurance for innovative drug market access, thus enhancing the commercial viability of these drugs [2] Aging Population and Long-term Care - The report mentions pilot programs for elderly care consumption subsidies, particularly for moderately to severely disabled seniors, which could drive demand for rehabilitation medical devices and related consumables [2] Investment Recommendations - The report suggests focusing on three key areas: 1. Innovative drugs with differentiated clinical value, recommending companies like BeiGene and Innovent Biologics [4] 2. Smart rehabilitation and home medical devices driven by long-term care insurance, recommending companies like Yuyue Medical and Sanofi [4] 3. AI and future industries, recommending companies with established commercial pathways in AI drug development and brain-computer interfaces, such as Jingtaikong and Yingshi Intelligent [4]

Core Viewpoint - The article outlines the key economic goals and tasks for 2026, emphasizing sustainable growth, employment generation, and advancements in various sectors, including technology and agriculture [2][7][10]. Economic Growth and Employment - The GDP growth target for 2026 is set between 4.5% and 5% [7]. - More than 12 million new urban jobs are expected to be created [8]. - The average annual growth rate of disposable income for residents is projected at 5.4% [5]. Agricultural and Industrial Production - The grain production target for 2026 is approximately 1.4 trillion jin [8]. - The manufacturing value-added scale is expected to maintain its global leadership [5]. - The production capacity for grain is aimed to reach 1.45 trillion jin [7]. Research and Development - The total R&D expenditure is expected to grow by over 7% annually [6]. - The average years of education for the working-age population is targeted to increase to 11.7 years [7]. Environmental Goals - A cumulative reduction of 17% in carbon dioxide emissions per unit of GDP is aimed for [6]. - The target for the reduction of carbon emissions in 2026 is approximately 3.8% [8]. Fiscal Policy and Budget - The budget deficit is projected to increase by 230 billion yuan, reaching a total deficit scale of 1.3 trillion yuan [8]. - The general public budget expenditure is expected to reach 30 trillion yuan for the first time [8]. - Special long-term bonds worth 1.3 trillion yuan are planned to be issued [8]. Sectoral Development Initiatives - The government plans to support emerging industries such as integrated circuits, aerospace, and biomedicine [10]. - Initiatives to promote future industries like quantum technology and 6G are also highlighted [10]. - Measures to enhance the agricultural sector through a national agricultural census and urbanization strategies are outlined [13].

Group 1 - China's innovation index has risen to 10th globally, with R&D investment expected to exceed 3.92 trillion yuan by 2025, reaching an intensity of 2.8% [4] - Basic research investment is close to 280 billion yuan, accounting for 7.08% of total R&D expenditure, marking a historical high [4] - Key areas for technological breakthroughs include integrated circuits, artificial intelligence, biomanufacturing, quantum technology, brain-computer interfaces, and nuclear fusion energy [5][6] Group 2 - By 2025, China's industrial added value is projected to reach 41.7 trillion yuan, contributing 35% to economic growth, further solidifying its position as the world's leading manufacturing power [9] - The development of advanced manufacturing is characterized by a focus on innovation, quality, and green practices [10] - The application rate of AI technology in large-scale manufacturing enterprises is expected to exceed 30% by the end of 2025, with over 300 humanoid robot products launched domestically [11] Group 3 - The core AI industry in China is anticipated to exceed 1.2 trillion yuan by 2025, with more than 6,200 companies operating in this sector [12] - Central enterprises' total assets have crossed 90 trillion yuan during the 14th Five-Year Plan, with profits increasing by 56.2% compared to the previous five years [16] - Revenue from strategic emerging industries surpassed 12 trillion yuan last year, with significant investments made in these sectors [17] Group 4 - Central enterprises are focusing on leading sectors such as new energy, aerospace, and new materials, with a strong emphasis on maintaining advantages in the new energy sector [19] - The production and revenue of new energy vehicles have doubled in three years, with market share for domestic brands increasing from 10% to 16.5% [19] - Central enterprises are also investing in emerging fields like quantum information, nuclear fusion, low-altitude economy, and biotechnology [19]

Group 1: Pharmaceutical and Biotechnology Sector - Four Seasons Pharmaceutical (00460) saw a stock increase of 3.7% after receiving approval from the NMPA for its innovative drug, Pyrocilin Tablets, for treating HR+/HER2- advanced breast cancer [1] - Hengrui Medicine (01276) rose over 5% following the approval of a clinical trial for HRS-1780 Tablets aimed at treating primary hyperaldosteronism [3] - Mirxes-B (02629) experienced a stock surge of 10.86% after announcing a strategic partnership with Apollo Health to develop advanced cancer early detection solutions in India [3] - Cornerstone Pharmaceuticals-B (02616) increased by 12.37% after receiving FDA approval for its IND application for CS2009, a tri-specific antibody for advanced solid tumors [4] - Deciphera Pharmaceuticals-B (06996) rose 16.77% after signing an agreement with U.S. Biotech for the global development and commercialization of ATG-201, a dual-specific T-cell engager [5] Group 2: Automotive Sector - Automotive stocks showed a collective rebound, with XPeng Motors-W (09868) up 3.14% and NIO-SW (09866) up 3.43%, driven by news of BYD's upcoming launch of its second-generation blade battery and fast-charging technology [2] Group 3: Technology and Communication Sector - Optical communication stocks rallied, with Cambridge Technology (06166) up 8.7% after NVIDIA announced a $40 billion investment in optical technology through partnerships with Lumentum and Coherent [1] - Brain-computer interface stocks surged, with Nanjing Panda Electronics (00553) increasing by 24.64% following government reports emphasizing the development of future industries, including brain-computer interfaces [2] Group 4: Cryptocurrency Sector - Cryptocurrency-related stocks rebounded, with Okex Cloud Chain (01499) rising 15.89% as Bitcoin surpassed $72,000, driven by short-covering amid geopolitical concerns [5][6]

Market Overview - The A-share market showed positive momentum with the ChiNext Index rising by 2.43%, the Shanghai Composite Index increasing by 0.84%, and the Shenzhen Component Index up by 1.67% [3][5] - The total trading volume in the Shanghai and Shenzhen markets reached 1.55 trillion yuan, a decrease of 91.8 billion yuan compared to the previous trading day, with over 4,500 stocks rising [5][6] Sector Performance - MiniLED and smart grid concept stocks experienced a surge, with many hitting the daily limit [5] - The brain-computer interface sector saw significant activity, with stocks like Rock Mountain Technology hitting the daily limit, driven by government reports emphasizing future industry investments [5][6] - Retail stocks were also active, with companies like Maoye Commercial hitting the daily limit, following government plans to adjust consumption tax policies [5] Key Indices - The ChiNext Index opened at 3,236.15, with a high of 3,264.80 and a low of 3,199.76, reflecting a market capitalization of 22.4 trillion yuan [4][8] - The Shanghai Composite Index opened at 4,109.78, showing a gain of 0.67% [8] Commodity Movements - The SC crude oil futures contract surged by 12%, currently priced at 699 yuan per barrel [12] - The shipping index for European routes saw a significant increase, with a rise of 11% to 2,033 points [13]

Group 1 - The core viewpoint of the news is that the Hong Kong pharmaceutical sector is experiencing a rebound, particularly in innovative drug stocks, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising over 3% after a period of decline [1][4] - The Hong Kong Stock Connect Innovative Drug ETF (520880) recorded five consecutive days of decline, reaching a historical low, but saw a capital inflow of over 135 million yuan during this period [1][2] - The healthcare sector in Hong Kong is showing signs of recovery, with major stocks like WuXi Biologics and BeiGene contributing to the rise of the Hong Kong Stock Connect Healthcare ETF [4][6] Group 2 - The total amount of business development (BD) for innovative drugs in China exceeded 50 billion USD in the first two months of 2026, with upfront payments surpassing 3 billion USD, indicating a strong growth trajectory [3] - Chinese pharmaceutical companies are entering a commercialization phase, with companies like Rongchang Bio turning a profit of 709 million yuan in 2025, and BeiGene achieving its first non-GAAP net profit [3] - China National Pharmaceutical Group's stock surged over 5% following the announcement of an exclusive licensing agreement with Sanofi, which includes an upfront payment of 135 million USD and potential milestone payments of up to 1.395 billion USD [1][3]

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing a rebound, particularly in innovative drug companies, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising over 3% after a five-day decline, indicating increased investor interest despite recent lows [1][8]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) opened high and is currently up over 3%, recovering from a historical low reached after five consecutive days of decline [1][8]. - The ETF has seen a net inflow of over 135 million yuan in the past five days, suggesting a strategic accumulation by investors [1][8]. - The Hong Kong medical sector ETF (159137) also opened higher, with significant contributions from major stocks like WuXi Biologics and BeiGene, indicating a broader market recovery [3][10]. Group 2: Company Developments - China National Pharmaceutical Group's stock surged over 5% following the announcement of an exclusive licensing agreement with Sanofi for a drug, which includes an upfront payment of $135 million and potential milestone payments totaling up to $1.395 billion [1][10]. - The innovative drug business development (BD) in China surpassed $50 billion in the first two months of 2026, with upfront payments nearing $3 billion, highlighting a significant growth trend in the sector [3][10]. - Companies like Rongchang Biologics and Junshi Biosciences are transitioning to profitability, with Rongchang expected to report a net profit of 709 million yuan in 2025 [3][10]. Group 3: Investment Opportunities - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds are positioned as efficient investment vehicles for those looking to capitalize on the innovative drug sector, with over 70% of the top ten holdings being leading companies [5][12]. - The Hong Kong medical ETF (159137) encompasses a wide range of innovative medical concepts, including brain-computer interfaces and AI healthcare, providing diverse investment opportunities [6][12].

十四届全国人大四次会议5日上午在人民大会堂开幕，习近平等党和国家领导人出席开幕会，国务院总理李强向大会作政府工作报告。 政府工作报告：培育壮大新兴产业和未来产业。建立未来产业投入增长和风险分担机制，培育发展未来能源、量子科技、具身智能、脑机接口、6G等未 来产业。 ...

Core Viewpoint - The exoskeleton industry is expected to evolve into an independent sector comparable to smartphones, addressing human mobility limitations and enhancing physical capabilities [2]. Group 1: Company Developments - Cheng Tian Technology secured a significant B+ round financing led by Agricultural Bank Capital, marking its second funding round in a year [2]. - The company plans to launch consumer-grade exoskeleton products in 2025, with an estimated shipment of 60,000 to 100,000 units in 2026 [3][9]. - The initial consumer product, a passive exoskeleton, sold out quickly, indicating strong market demand [7]. Group 2: Product Features and User Feedback - The passive exoskeleton targets individuals with walking disabilities, receiving positive feedback for improving stability and gait, although it has limitations in high-load scenarios like climbing [7]. - Active exoskeletons are being developed to assist with joint pain and fatigue during physical activities, with applications in scenic areas [8]. - The company emphasizes the importance of user-specific needs, suggesting that different demographics require tailored exoskeleton solutions [14][15]. Group 3: Market Trends and Future Outlook - The exoskeleton market is still in its infancy, with significant growth potential driven by aging populations and increasing consumer interest [10][18]. - The company aims to differentiate its products through precise user profiling and targeted functionalities rather than creating a one-size-fits-all solution [12][14]. - AI applications in exoskeletons focus on enhancing human-machine interaction and personalizing user experiences through data-driven insights [24][25]. Group 4: Supply Chain and Production Challenges - The supply chain for exoskeleton components has improved, allowing for better cost control and scalability, which was previously a major barrier [11]. - The company has opted for in-house manufacturing to address the rapid product iteration demands and ensure quality standards [11][12]. - The core indicators for consumer-grade exoskeletons include weight, battery life, and stability, which are influenced by supply chain capabilities [12]. Group 5: Integration of AI and Advanced Technologies - AI is being utilized for personalized adaptations of exoskeletons, enhancing user experience through real-time data analysis [24][25]. - The company is also developing brain-machine interfaces to further integrate exoskeletons with human physiology, aiming to improve rehabilitation outcomes [31][32]. - Continuous data collection from clinical applications is crucial for refining product designs and enhancing user adaptability [30].